传统抗凝药、新型抗凝药及抗血小板药对鼻出血的影响
该回顾性研究分析了2012至2018年因鼻出血就诊于三级医院急诊的470例患者,其中241例使用抗凝/抗血小板药物。结果显示,使用抗凝/抗血小板药物者严重鼻出血和住院风险更高,但复发风险与对照组相似;华法林和依诺肝素增加严重鼻出血、住院、后鼻孔填塞、显著失血及输血风险,而新型口服抗凝药(NOAC)未显示这些风险增加。
要点
- 使用抗凝/抗血小板药物者严重鼻出血风险高(OR=1.8),住院风险高(OR=2.17),但复发风险相似(15%)。
- 华法林和依诺肝素增加严重鼻出血(OR=4.4)、住院(OR=2.1)、后鼻孔填塞(OR=19)、显著失血(OR=4.4)和输血(OR=4.7)风险。
- NOAC与对照组相比,未增加严重鼻出血、住院、填塞、显著失血或输血风险。
核心结论
- 与老一代抗凝药和抗血小板药相比,NOAC在鼻出血严重程度、住院需求和结局方面表现出更好的安全性。
主要发现
- ACAP组严重鼻出血风险高于对照组(OR=1.8,P<.05),住院风险更高(OR=2.17,P<.05),但复发风险相似(15%,P>.05)。
- 与对照组相比,华法林和依诺肝素增加严重鼻出血风险(OR=4.4,P<.05)和住院风险(OR=2.1,P<.05),并增加后鼻孔填塞风险(OR=19,P<.001)、显著失血风险(OR=4.4,P=.032)和输血风险(OR=4.7,P=.007)。
- NOAC与对照组相比,未增加严重鼻出血、住院、填塞、显著失血或输血风险。
临床怎么用
- 对于接受NOAC治疗的患者,鼻出血处理可能可采取更保守的方法并减少住院。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/HYPOTHESIS: Anticoagulant and antiplatelet medications (ACAP) are known to be associated with an increased risk for epistaxis. There are conflicting results regarding the impact of Novel Oral Anticoagulants (NOAC) on epistaxis and its severity. STUDY DESIGN: Retrospective chart review of patients who were admitted to the ED in our tertiary level hospital with a diagnosis of epistaxis during the years 2012 to 2018. METHODS: Retrospective analysis of patients presenting to tertiary level emergency otolaryngological care during the years 2012 to 2018. The impact of various ACAP medications on epistaxis severity, hospital admission, and recurrence was analyzed. RESULTS: A total of 470 patients were identified. Two hundred and twenty-nine patients (49%), were not on any anticoagulant/antiplatelet (ACAP) medications (controls) and 241 patients (51%) were taking at least one ACAP medication (ACAP group). Patients in the ACAP group were at a higher risk for severe epistaxis (OR = 1.8, P < .05) and were more likely to be hospitalized (OR = 2.17, P < .05). Surprisingly, the risk for recurrence was similar in the ACAP and control groups (15%, P > .05). Compared to controls, Warfarin and Enoxaparin increased the overall risk for severe epistaxis (OR = 4.4, P < .05) and for hospital admission (OR = 2.1, P < .05). Specifically, an increased risk for posterior tamponade (OR = 19, P < .001), significant blood loss (OR = 4.4, P = .032), and blood transfusion (OR = 4.7, P = .007) were identified as well. Interestingly, NOACs were not associated with increased risk for severe epistaxis, hospital admission, tamponade, and significant blood loss or blood transfusion compared to controls. CONCLUSIONS: Compared to older generation anticoagulants and antiplatelet medications, NOACs demonstrated an improved safety profile, in terms of epistaxis severity, need for hospital admission and outcomes. These results may suggest a more conservative approach and less hospitalization when treating epistaxis in patients receiving NOACs. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:1946-1951, 2021.
引用
- Yaniv D, Zavdy O, Sapir E, et al. The Impact of Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on Epistaxis. Laryngoscope. 2021. PMID: 33533493. doi:10.1002/lary.29417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。